Galderma Has Received Regulatory Approval for Restylane® SHAYPE™, a Novel Hyaluronic Acid Injectable Designed for Enhancing the Chin Region

Galderma, a leading player in the dermatology industry, has recently obtained approval from Health Canada for its latest hyaluronic acid (HA) injectable, Restylane® SHAYPE™. This innovative product is specifically designed for temporary chin augmentation, addressing concerns related to chin definition and facial balance. The approval paves the way for the availability of Restylane® SHAYPE™ in Canada starting February 2024.The chin is a critical aspect of overall facial appearance, influencing factors such as facial proportions, profile, and shape. Genetic factors and the aging process can impact chin definition, resulting in issues such as a double chin or a "weak chin." Traditionally, surgical implants have been the conventional solution for enhancing lower face structure, with limited non-surgical alternatives.Restylane® SHAYPE™, powered by Galderma's new NASHA HD™ technology, features the highest G' ("G prime") in the Restylane® range. As the firmest HA gel currently available, it enables aesthetic injectors to shape, project, and elongate the chin for natural-looking results from any angle. Notably, Restylane® SHAYPE™ is minimally modified, closely resembling the natural HA found in the skin, and can be easily reversed.In a pivotal 12-month study conducted at multiple sites in Canada, 91% of patients reported sustained aesthetic improvements, with 84% expressing willingness to undergo Restylane® SHAYPE™ treatment again. Impressively, up to 97% of patients would recommend the treatment to others, and 95% felt that their results appeared natural.Dr. Baldo Scassellati Sforzolini, Global Head of R&D at Galderma, emphasized that Restylane® SHAYPE™ represents the next generation in HA, surpassing existing options for chin augmentation. The product's unique ability to create a bone-mimicking effect makes it an ideal choice for lower face shaping, providing long-lasting, natural-looking results for up to 12 months without the need for retreatment.Dr. Andreas Nikolis, Principal Investigator of the Restylane® SHAYPE™ pivotal study, noted the significant demand for a product capable of mimicking bone effects without surgical downtime. Galderma's meticulous clinical evaluation has resulted in the development of a safe and effective HA injectable for chin remodeling.Galderma is actively pursuing regulatory approvals in other countries, with the goal of introducing this groundbreaking innovation to a global audience. The RESTYLANE® portfolio, produced using NASHA HD™ technology, represents over 27 years of clinical experience and has been utilized in over 65 million treatments worldwide, making it the most diverse range of fillers for various aesthetic needs.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!